Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eton Pharmaceutcials Inc (NQ: ETON )

5.629 -0.271 (-4.60%)
Streaming Delayed Price Updated: 11:48 AM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 52,890
Open 5.890
Bid (Size) 5.620 (2)
Ask (Size) 5.660 (5)
Prev. Close 5.900
Today's Range 5.629 - 5.910
52wk Range 3.030 - 6.020
Shares Outstanding 25,688,062
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Eton Pharmaceuticals
Via GlobeNewswire
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+22.63%
+22.63%
1 Month
+36.62%
+36.62%
3 Month
+70.56%
+70.56%
6 Month
+55.49%
+55.49%
1 Year
+21.05%
+21.05%

More News

Read More
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
Recap: Eton Pharmaceuticals Q4 Earnings
Via Benzinga
Eton Pharmaceuticals Earnings Preview
Via Benzinga
Is NASDAQ:ETON suited for growth investing?
Via Chartmill
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Via ACCESSWIRE
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
ETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Why the growth investor may take a look at NASDAQ:ETON.
Via Chartmill
Evaluating NASDAQ:ETON for Growth Investment Opportunities.
Via Chartmill
Eton Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
From Eton Pharmaceuticals
Via GlobeNewswire
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For March 14, 2024
Via Benzinga
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.